scholarly journals A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C

1997 ◽  
Vol 11 (7) ◽  
pp. 579-582 ◽  
Author(s):  
Masafumi Komatsu ◽  
Tsuyoshi Ono ◽  
Ko Nakajima ◽  
Itaru Toyoshima ◽  
Mitsuro Chiba ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Dose Group ◽  
Controlled Trial ◽  
Complete Response ◽  
High Dose ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

Sixty-one chronic hepatitis C patients were randomly assigned to receive either 6x106or 9x106U of recombinant interferon-alpha-2a (IFNα-2a) six days a week for the first two weeks of treatment, followed in both cases by 6x106U three days a week for the next 22 weeks. In the low dose group, 11 patients showed a complete response maintained for at least six months, 12 responded but then relapsed and nine did not respond; the corresponding figures in the high dose group were 10, 15 and five patients, respectively. The differences between groups are not statistically significant. Thus, this study provides no evidence of therapeutic benefit from increasing the initial dose of IFNα-2a. In both treatment groups, complete responders had significantly lower pretreatment viral titres than nonresponders and were significantly more likely to be infected by type 2a versus type 1b virus.

scholarly journals A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs

Blood ◽  
1991 ◽  
Vol 78 (7) ◽  
pp. 1672-1677 ◽  
Author(s):  
M Makris ◽  
FE Preston ◽  
DR Triger ◽  
JC Underwood ◽  
L Westlake ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Recombinant Interferon ◽  
Randomized Controlled ◽  
Ifn Alpha ◽  
Recombinant Interferon Alpha

Chronic liver disease associated with hepatitis C virus (HCV) is an important cause of morbidity and mortality in hemophilia. We have used recombinant interferon alpha-2b (IFN alpha-2b) in a randomized controlled liver biopsy trial to treat hemophiliacs with chronic hepatitis. Eighteen patients entered the study, 16 of whom were subsequently shown to have antibodies to the HCV. All underwent liver biopsy at entry and were randomized to either treatment with self- administered IFN alpha-2b, 3 million units subcutaneously thrice weekly (n = 10) or no treatment (control group) (n = 8). Nine subjects had chronic active hepatitis, seven had chronic persistent hepatitis, and two had cirrhosis. Twelve months after entry into the study 17 patients underwent a second liver biopsy. All biopsies were coded, assessed, and scored according to the histologic severity of the liver disease. Ten patients were administered IFN for 1 year, and in four patients normalization of alanine aminotransferase (ALT) occurred compared with none in the untreated group. After the second liver biopsy, six of the eight initial no-treatment patients were treated with interferon 3 million units thrice weekly for 6 months, and normalization of ALT was seen in five patients. Biochemical relapse within 4 months of stopping IFN occurred in one of four patients treated for 1 year and in four of five patients treated for 6 months. IFN treatment was well tolerated. Although the histologic scores of the two groups were similar at entry into the study, after 12 months the biopsy appearances in the treated group were significantly improved compared with the controls (P less than .01). Histologic improvement was noted in the three interferon- treated human immunodeficiency virus antibody-positive patients and also in other patients who had no biochemical response. We conclude that low-dose recombinant IFN alpha is effective in normalizing transaminases and improving the histologic appearances in at least 50% of hemophiliacs with chronic hepatitis C.

scholarly journals A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs

Blood ◽  
1991 ◽  
Vol 78 (7) ◽  
pp. 1672-1677 ◽  
Author(s):  
M Makris ◽  
FE Preston ◽  
DR Triger ◽  
JC Underwood ◽  
L Westlake ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Recombinant Interferon ◽  
Randomized Controlled ◽  
Ifn Alpha ◽  
Recombinant Interferon Alpha

Abstract Chronic liver disease associated with hepatitis C virus (HCV) is an important cause of morbidity and mortality in hemophilia. We have used recombinant interferon alpha-2b (IFN alpha-2b) in a randomized controlled liver biopsy trial to treat hemophiliacs with chronic hepatitis. Eighteen patients entered the study, 16 of whom were subsequently shown to have antibodies to the HCV. All underwent liver biopsy at entry and were randomized to either treatment with self- administered IFN alpha-2b, 3 million units subcutaneously thrice weekly (n = 10) or no treatment (control group) (n = 8). Nine subjects had chronic active hepatitis, seven had chronic persistent hepatitis, and two had cirrhosis. Twelve months after entry into the study 17 patients underwent a second liver biopsy. All biopsies were coded, assessed, and scored according to the histologic severity of the liver disease. Ten patients were administered IFN for 1 year, and in four patients normalization of alanine aminotransferase (ALT) occurred compared with none in the untreated group. After the second liver biopsy, six of the eight initial no-treatment patients were treated with interferon 3 million units thrice weekly for 6 months, and normalization of ALT was seen in five patients. Biochemical relapse within 4 months of stopping IFN occurred in one of four patients treated for 1 year and in four of five patients treated for 6 months. IFN treatment was well tolerated. Although the histologic scores of the two groups were similar at entry into the study, after 12 months the biopsy appearances in the treated group were significantly improved compared with the controls (P less than .01). Histologic improvement was noted in the three interferon- treated human immunodeficiency virus antibody-positive patients and also in other patients who had no biochemical response. We conclude that low-dose recombinant IFN alpha is effective in normalizing transaminases and improving the histologic appearances in at least 50% of hemophiliacs with chronic hepatitis C.

TREATMENT OF CHRONIC HEPATITIS C WITH RECOMBINANT INTERFERON ALPHA IN KIDNEY TRANSPLANT RECIPIENTS

1995 ◽  
Vol 59 (10) ◽  
pp. 1426-1431 ◽  
Author(s):  
Lionel Rostaing ◽  
Jacques Izopet ◽  
Emmanuel Baron ◽  
Michel Duffaut ◽  
Jacqueline Puel ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Kidney Transplant ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha
Sign in / Sign up

Export Citation Format

Share Document